Access
To read this story in full you will need to login or make a payment (see right).
Insight
Nature 441, 451-456 (25 May 2006) | doi:10.1038/nature04873; Published online 24 May 2006
Open Innovation Challenges
-
Methods of Modeling Adaptation in Populations
The analysis of adaptation with a population is a frequently encountered computational modeling scen...
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
- More Challenges
- Powered by:
nature jobs
International PhD Programme
- MRC Laboratory of Molecular Biology
- Cambridge, UK
Manager for the Recently Established Fly Facility
- Max-Planck-Institute of Immunobiology
- Freiburg Germany
Review Article Validating cancer drug targets
John D. Benson1, Ying-Nan P. Chen1, Susan A. Cornell-Kennon1, Marion Dorsch1, Sunkyu Kim1, Magdalena Leszczyniecka1, William R. Sellers1 & Christoph Lengauer1
Abstract
A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as 'validated' before investing in a full-scale drug discovery programme dedicated to it. Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established.
To read this story in full you will need to login or make a payment (see right).
